Candel Therapeutics (CADL) Director Martine Zimmermann Receives Award

What Happened

• Martine Zimmermann, a director of Candel Therapeutics (CADL), received an award on 2026-09-08 covering 64,000 derivative shares. The filing shows an acquisition price of $0.00 for the award (reported as transaction code A — grant/award).
• This was a grant of derivative securities (an equity award/option-like instrument), not a cash purchase or sale. No immediate cash value or proceeds were reported.

Key Details

• Transaction date: 2026-09-08; Filing date: 2026-09-10 (appears timely under Form 4 rules).
• Amount: 64,000 derivative shares; Reported price: $0.00 (award/grant).
• Shares owned after transaction: Not specified in the provided summary of the Form 4.
• Footnote: The award “shall vest and become exercisable in thirty-six (36) equal monthly installments,” subject to Zimmermann’s continued service on each vesting date.
• No 10b5-1, tax-withholding, or sale activity was reported in this filing.

Context

• Director grants like this are common as compensation and are typically intended to align long-term interests with shareholders; the vesting schedule spreads potential ownership over three years.
• Because this is an award (not a purchase or sale) and vests over time, it does not indicate an immediate market view or liquidity event by the insider.